Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial

OBJECTIVES: To report toxicity (primary endpoint) and biochemical disease‐free survival (BDFS) outcomes of a phase II trial evaluating ultra‐hypofractionated radiation therapy (UHRT), focusing on patients with unfavourable intermediate‐risk and high‐risk prostate cancer (PCa). PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Macias, Victor A., Barrera‐Mellado, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003804/
https://www.ncbi.nlm.nih.gov/pubmed/31614071
http://dx.doi.org/10.1111/bju.14925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003804/
https://www.ncbi.nlm.nih.gov/pubmed/31614071
http://dx.doi.org/10.1111/bju.14925

Ejemplares similares